陈去氧胆酸治疗脑黄疽成人患者的评估:一项随机、安慰剂对照的3期研究

IF 3.6 3区 医学 Q2 PHARMACOLOGY & PHARMACY Journal of clinical lipidology Pub Date : 2024-07-01 DOI:10.1016/j.jacl.2024.04.069
Andrea DeBarber PhD, Yaz Kisanuki MD, Paulo Nobrega MD, Ryan Himes MD, Suman Jayadev MD, John Bernat MD, Vikram Prakash MD, James Gibson MD, Austin Larson MD, Paulo Sgobbi PhD, Edward Murphy MS, Brian Fedor BS, Cheryl Wong Po Foo PhD, Rana Dutta PhD, Michael Imperiale MD, Will Garner PhD, Pamela Vig PhD, Sarah Perez MD, Ritesh Ramdhani MD, Jonas Saute MD, P. Barton Duell MD
{"title":"陈去氧胆酸治疗脑黄疽成人患者的评估:一项随机、安慰剂对照的3期研究","authors":"Andrea DeBarber PhD,&nbsp;Yaz Kisanuki MD,&nbsp;Paulo Nobrega MD,&nbsp;Ryan Himes MD,&nbsp;Suman Jayadev MD,&nbsp;John Bernat MD,&nbsp;Vikram Prakash MD,&nbsp;James Gibson MD,&nbsp;Austin Larson MD,&nbsp;Paulo Sgobbi PhD,&nbsp;Edward Murphy MS,&nbsp;Brian Fedor BS,&nbsp;Cheryl Wong Po Foo PhD,&nbsp;Rana Dutta PhD,&nbsp;Michael Imperiale MD,&nbsp;Will Garner PhD,&nbsp;Pamela Vig PhD,&nbsp;Sarah Perez MD,&nbsp;Ritesh Ramdhani MD,&nbsp;Jonas Saute MD,&nbsp;P. Barton Duell MD","doi":"10.1016/j.jacl.2024.04.069","DOIUrl":null,"url":null,"abstract":"<div><h3>Study Funding</h3><p>Mirum Pharmaceuticals, Inc.</p></div><div><h3>Background/Synopsis</h3><p>Cerebrotendinous xanthomatosis (CTX) is a rare metabolic disorder of bile acid synthesis caused by biallelic pathogenic variants in the CYP27A1 gene, encoding the sterol 27-hydroxylase enzyme, which leads to abnormal bile acid synthesis and toxic accumulation of cholestanol, bile alcohols and other metabolites. Chenodeoxycholic acid (CDCA) treatment is considered the standard-of-care for CTX.</p></div><div><h3>Objective/Purpose</h3><p>We evaluated the efficacy and safety of CDCA on biomarkers of CTX in the first Phase 3, randomized withdrawal, double-blind (DB), placebo (PBO)-controlled, two-period x two-treatment cross-over study with rescue medication (RESTORE).</p></div><div><h3>Methods</h3><p>A 24-week randomized withdrawal, DB, crossover study with a 30-day safety follow-up was conducted in adult patients (≥16 years of age) with CTX who received 250 mg CDCA TID for two 8-week open label (OL) periods of the study and either blinded CDCA or PBO for two 4-week DB periods. Eligible participants had a clinical diagnosis of CTX with biochemical confirmation, no known malabsorption or GI conditions, and not on cholic acid and/or medication impacting bile acid absorption. The primary endpoint was change in the urinary bile alcohol biomarker 5β-cholestane-3α,7α,12α,23S,25-pentol (23S-pentol) from Baseline (BL) to the end of each DB treatment period. Key secondary efficacy endpoints included: percent changes in plasma cholestanol and 7α-hydroxy-4-cholesten-3-one (7αC4) at end of each DB period and proportion of patients requiring rescue medication (CDCA) during the DB periods. Safety parameters were also assessed.</p></div><div><h3>Results</h3><p>The analysis included 14 participants with a median (min, max) age at enrollment of 41.5 (16, 55) years, the majority were white males, and all had a clinical diagnosis of CTX with biochemical confirmation. CDCA withdrawal after the OL treatment period resulted in a statistically significant 20-fold increase (95% CI: 10.3, 43.5 p&lt;0.0001) in urine 23S-pentol (ng/mL), a 2.8-fold increase (95% CI: 1.5, 5.2; p=0.0083) in plasma cholestanol (µg/mL), and a 50-fold increase (95% CI: 25.0, 66.7; p&lt;0.0001) in plasma 7αC4 (ng/mL; placebo relative to CDCA). A significant proportion of participants on PBO (61.5% [95% CI: 31.6, 86.1]; p=0.0006) required blinded rescue medication during the DB withdrawal periods. Most commonly reported TEAEs on CDCA were diarrhea (n=5) and headache (n=3) with the majority mild to moderate in severity and not considered treatment related.</p></div><div><h3>Conclusions</h3><p>Withdrawal of CDCA treatment led to significant increases in CTX biomarkers. CDCA treatment is well-tolerated and can effectively suppress abnormal bile acid synthesis in CTX, preventing accumulation of cholestanol and bile alcohols. This underscores the potential for CDCA to help CTX patients avoid disease progression.</p></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"18 4","pages":"Pages e540-e541"},"PeriodicalIF":3.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"†Evaluation of Chenodeoxycholic Acid Treatment in Adult Patients with Cerebrotendinous Xanthomatosis: A Randomized, Placebo-Controlled Phase 3 Study\",\"authors\":\"Andrea DeBarber PhD,&nbsp;Yaz Kisanuki MD,&nbsp;Paulo Nobrega MD,&nbsp;Ryan Himes MD,&nbsp;Suman Jayadev MD,&nbsp;John Bernat MD,&nbsp;Vikram Prakash MD,&nbsp;James Gibson MD,&nbsp;Austin Larson MD,&nbsp;Paulo Sgobbi PhD,&nbsp;Edward Murphy MS,&nbsp;Brian Fedor BS,&nbsp;Cheryl Wong Po Foo PhD,&nbsp;Rana Dutta PhD,&nbsp;Michael Imperiale MD,&nbsp;Will Garner PhD,&nbsp;Pamela Vig PhD,&nbsp;Sarah Perez MD,&nbsp;Ritesh Ramdhani MD,&nbsp;Jonas Saute MD,&nbsp;P. Barton Duell MD\",\"doi\":\"10.1016/j.jacl.2024.04.069\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Study Funding</h3><p>Mirum Pharmaceuticals, Inc.</p></div><div><h3>Background/Synopsis</h3><p>Cerebrotendinous xanthomatosis (CTX) is a rare metabolic disorder of bile acid synthesis caused by biallelic pathogenic variants in the CYP27A1 gene, encoding the sterol 27-hydroxylase enzyme, which leads to abnormal bile acid synthesis and toxic accumulation of cholestanol, bile alcohols and other metabolites. Chenodeoxycholic acid (CDCA) treatment is considered the standard-of-care for CTX.</p></div><div><h3>Objective/Purpose</h3><p>We evaluated the efficacy and safety of CDCA on biomarkers of CTX in the first Phase 3, randomized withdrawal, double-blind (DB), placebo (PBO)-controlled, two-period x two-treatment cross-over study with rescue medication (RESTORE).</p></div><div><h3>Methods</h3><p>A 24-week randomized withdrawal, DB, crossover study with a 30-day safety follow-up was conducted in adult patients (≥16 years of age) with CTX who received 250 mg CDCA TID for two 8-week open label (OL) periods of the study and either blinded CDCA or PBO for two 4-week DB periods. Eligible participants had a clinical diagnosis of CTX with biochemical confirmation, no known malabsorption or GI conditions, and not on cholic acid and/or medication impacting bile acid absorption. The primary endpoint was change in the urinary bile alcohol biomarker 5β-cholestane-3α,7α,12α,23S,25-pentol (23S-pentol) from Baseline (BL) to the end of each DB treatment period. Key secondary efficacy endpoints included: percent changes in plasma cholestanol and 7α-hydroxy-4-cholesten-3-one (7αC4) at end of each DB period and proportion of patients requiring rescue medication (CDCA) during the DB periods. Safety parameters were also assessed.</p></div><div><h3>Results</h3><p>The analysis included 14 participants with a median (min, max) age at enrollment of 41.5 (16, 55) years, the majority were white males, and all had a clinical diagnosis of CTX with biochemical confirmation. CDCA withdrawal after the OL treatment period resulted in a statistically significant 20-fold increase (95% CI: 10.3, 43.5 p&lt;0.0001) in urine 23S-pentol (ng/mL), a 2.8-fold increase (95% CI: 1.5, 5.2; p=0.0083) in plasma cholestanol (µg/mL), and a 50-fold increase (95% CI: 25.0, 66.7; p&lt;0.0001) in plasma 7αC4 (ng/mL; placebo relative to CDCA). A significant proportion of participants on PBO (61.5% [95% CI: 31.6, 86.1]; p=0.0006) required blinded rescue medication during the DB withdrawal periods. Most commonly reported TEAEs on CDCA were diarrhea (n=5) and headache (n=3) with the majority mild to moderate in severity and not considered treatment related.</p></div><div><h3>Conclusions</h3><p>Withdrawal of CDCA treatment led to significant increases in CTX biomarkers. CDCA treatment is well-tolerated and can effectively suppress abnormal bile acid synthesis in CTX, preventing accumulation of cholestanol and bile alcohols. This underscores the potential for CDCA to help CTX patients avoid disease progression.</p></div>\",\"PeriodicalId\":15392,\"journal\":{\"name\":\"Journal of clinical lipidology\",\"volume\":\"18 4\",\"pages\":\"Pages e540-e541\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of clinical lipidology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1933287424001168\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical lipidology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1933287424001168","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

研究经费Mirum Pharmaceuticals, Inc.背景/简介脑膜黄瘤病(CTX)是一种罕见的胆汁酸合成代谢性疾病,由编码甾醇27-羟化酶的CYP27A1基因的双倍性致病变异引起,导致胆汁酸合成异常以及胆甾醇、胆汁醇和其他代谢产物的毒性蓄积。目标/目的我们在第一项3期随机停药、双盲(DB)、安慰剂(PBO)对照、两阶段x两治疗交叉研究(RESTORE)中评估了CDCA对CTX生物标志物的疗效和安全性。方法在成年 CTX 患者(≥16 岁)中开展了一项为期 24 周的随机停药、DB、交叉研究,并进行了 30 天的安全性随访,这些患者在研究的两个 8 周开放标签 (OL) 期接受 250 毫克 CDCA TID,并在两个 4 周 DB 期接受盲法 CDCA 或 PBO。符合条件的参与者须经临床诊断并经生化证实患有 CTX,无已知的吸收不良或消化道疾病,且未服用胆酸和/或影响胆汁酸吸收的药物。主要终点是尿胆汁醇生物标志物 5β-胆甾烷-3α,7α,12α,23S,25-戊醇(23S-pentol)从基线(BL)到每个 DB 治疗期结束时的变化。关键的次要疗效终点包括:每个 DB 治疗期结束时血浆胆甾醇和 7α-hydroxy-4-cholesten-3-one (7αC4) 的变化百分比,以及 DB 治疗期间需要抢救药物 (CDCA) 的患者比例。结果分析纳入了 14 名参与者,入组时的中位(最小,最大)年龄为 41.5(16,55)岁,大多数为白人男性,所有患者均被临床诊断为 CTX,并经生化确诊。在 OL 治疗期后停用 CDCA 会导致尿液中 23S-pentol (ng/mL) 增加 20 倍(95% CI:10.3, 43.5 p<0.0001),尿液中 23S-pentol (ng/mL) 增加 2.8 倍(95% CI:10.3, 43.5 p<0.0001)。血浆胆甾醇(µg/mL)增加 8 倍(95% CI:1.5,5.2;p=0.0083),血浆 7αC4(ng/mL;安慰剂相对于 CDCA)增加 50 倍(95% CI:25.0,66.7;p<0.0001)。相当一部分服用 PBO 的参与者(61.5% [95% CI:31.6, 86.1];p=0.0006)在 DB 停药期间需要使用盲法抢救药物。CDCA最常报告的TEAEs是腹泻(5例)和头痛(3例),大多数为轻度至中度,不认为与治疗有关。CDCA 治疗耐受性良好,能有效抑制 CTX 中异常胆汁酸合成,防止胆甾醇和胆汁醇的积累。这凸显了 CDCA 帮助 CTX 患者避免疾病恶化的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
†Evaluation of Chenodeoxycholic Acid Treatment in Adult Patients with Cerebrotendinous Xanthomatosis: A Randomized, Placebo-Controlled Phase 3 Study

Study Funding

Mirum Pharmaceuticals, Inc.

Background/Synopsis

Cerebrotendinous xanthomatosis (CTX) is a rare metabolic disorder of bile acid synthesis caused by biallelic pathogenic variants in the CYP27A1 gene, encoding the sterol 27-hydroxylase enzyme, which leads to abnormal bile acid synthesis and toxic accumulation of cholestanol, bile alcohols and other metabolites. Chenodeoxycholic acid (CDCA) treatment is considered the standard-of-care for CTX.

Objective/Purpose

We evaluated the efficacy and safety of CDCA on biomarkers of CTX in the first Phase 3, randomized withdrawal, double-blind (DB), placebo (PBO)-controlled, two-period x two-treatment cross-over study with rescue medication (RESTORE).

Methods

A 24-week randomized withdrawal, DB, crossover study with a 30-day safety follow-up was conducted in adult patients (≥16 years of age) with CTX who received 250 mg CDCA TID for two 8-week open label (OL) periods of the study and either blinded CDCA or PBO for two 4-week DB periods. Eligible participants had a clinical diagnosis of CTX with biochemical confirmation, no known malabsorption or GI conditions, and not on cholic acid and/or medication impacting bile acid absorption. The primary endpoint was change in the urinary bile alcohol biomarker 5β-cholestane-3α,7α,12α,23S,25-pentol (23S-pentol) from Baseline (BL) to the end of each DB treatment period. Key secondary efficacy endpoints included: percent changes in plasma cholestanol and 7α-hydroxy-4-cholesten-3-one (7αC4) at end of each DB period and proportion of patients requiring rescue medication (CDCA) during the DB periods. Safety parameters were also assessed.

Results

The analysis included 14 participants with a median (min, max) age at enrollment of 41.5 (16, 55) years, the majority were white males, and all had a clinical diagnosis of CTX with biochemical confirmation. CDCA withdrawal after the OL treatment period resulted in a statistically significant 20-fold increase (95% CI: 10.3, 43.5 p<0.0001) in urine 23S-pentol (ng/mL), a 2.8-fold increase (95% CI: 1.5, 5.2; p=0.0083) in plasma cholestanol (µg/mL), and a 50-fold increase (95% CI: 25.0, 66.7; p<0.0001) in plasma 7αC4 (ng/mL; placebo relative to CDCA). A significant proportion of participants on PBO (61.5% [95% CI: 31.6, 86.1]; p=0.0006) required blinded rescue medication during the DB withdrawal periods. Most commonly reported TEAEs on CDCA were diarrhea (n=5) and headache (n=3) with the majority mild to moderate in severity and not considered treatment related.

Conclusions

Withdrawal of CDCA treatment led to significant increases in CTX biomarkers. CDCA treatment is well-tolerated and can effectively suppress abnormal bile acid synthesis in CTX, preventing accumulation of cholestanol and bile alcohols. This underscores the potential for CDCA to help CTX patients avoid disease progression.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.00
自引率
6.80%
发文量
209
审稿时长
49 days
期刊介绍: Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.
期刊最新文献
Burden of atherogenic lipids and association with cardiac allograft vasculopathy in heart transplant recipients. Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America. Identification and functional analysis of novel homozygous LMF1 variants in severe hypertriglyceridemia. Complex dyslipidemia induced by Lorlatinib therapy: A case study. Lipoprotein(a) in clinical practice: The role in long-term in-stent restenosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1